Abstract Library

#3330 Effects of transplantation related immunosuppression on co-existent neuroendocrine tumors

Introduction: Here we detail our experience of managing patients found with NETs whilst on immunosuppression for a transplanted organ or receiving an organ from a donor with a NET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Shah H

Authors: Shah H, Faulkes R, Shetty S, Shah T,

Keywords: neuroendocrine tumor, immunosuppression, transplantation,

#2280 The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents

Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Briest F

Authors: Briest F, Grötzinger C, Exner S, Sedding D, Baum R,

Keywords: peptide radioreceptor therapy, Lu-177-DOTATOC, PRRT, bortezomib, in vivo model, SPECT/CT Imaging, chicken CAM model, Sensitizer, DNA damage repair,

#2225 Long Term Survival after Transplant for Neuroendocrine Liver Metastases: A Case Report and Literature Review

Introduction: Liver transplantation (LT) is offered to selected patients of neuroendocrine tumours (NETs) with unresectable liver metastases (NELM).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Pande P

Authors: Pande P, Desai G, Shah R, Palepu J,

Keywords: : neuroendocrine tumours, liver metastases, liver transplantation,

#1867 Establishment of the First Well-Differentiated in Vivo Human Pancreatic Neuroendocrine Tumor Model

Introduction: The development of new therapeutic strategies for cancer patients relies on the in vitro and in vivo testing of novel substances in the pre-clinical setting. So far, this has not been possible for pancreatic neuroendocrine tumors (pNET) due to lack of suitable animal models resembling the disease course in human patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Schrader J, Unrau L, Stahl F, Eggers C, Fahl M,

Keywords: pNET, insulinoma, SSTR,

#1591 Patient-Reported Preferences in Treatments Approved in Neuroendocrine Tumors: A National Survey from the French Group of Endocrine Tumors

Introduction: Patients with advanced neuroendocrine tumors (NETs) benefit from an increasing number of treatments. The patient’s preference could help physicians to choose among these options

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Thomas W

Authors: Plante A, Baudin E, Do Cao C, Hentic O, Dubreuil O,

Keywords: neuroendocrine tumor, toxicity, PRO,